Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 4/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28223602 | 1.00 | ABCB1 (0.37) | ABCB1DPP7TSHRALDH1A1CCR6 | |
| SCHEMBL27148693 | 1.00 | ABCB1 (0.37) | ABCB1DPP7TSHRALDH1A1CCR6 | |
| SCHEMBL27150036 | 1.00 | ABCB1 (0.37) | ABCB1DPP7TSHRALDH1A1CCR6 | |
| SCHEMBL27137245 | 1.00 | ABCB1 (0.37) | ABCB1DPP7TSHRALDH1A1CCR6 | |
| SCHEMBL2130748 | 0.98 | TSHR (0.36) | ABCB1DPP7TSHRALDH1A1CCR6 | |
| SCHEMBL16760609 | 0.91 | CCR5 (0.40) | ABCB1TSHRCCR5 | |
| SCHEMBL9062253 | 0.91 | CCR5 (0.40) | ABCB1TSHRCCR5 | |
| SCHEMBL11229187 | 0.91 | CCR5 (0.40) | ABCB1TSHRCCR5 | |
| SCHEMBL15467638 | 0.91 | CCR5 (0.40) | ABCB1TSHRCCR5 | |
| SCHEMBL9801267 | 0.91 | CCR5 (0.40) | ABCB1TSHRCCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327421-A1 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | CU Ventures, Inc. | 2024-10-03 | — | — | US | disclosed |
| EP-3601204-A1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOALKANE AND (4'-HYDROXYPHENYL)CYCLOALKENE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM FOR ENHANCED MEMORY CONSOLIDATION | Marquette University (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10144879-B2 | Hydrocarbon synthesis methods, apparatus, and systems | SARTEC CORPORATION (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018183800-A1 | SUBSTITUTED (4'-HYDROXYPHENYL)CYCLOALKANE AND (4'-HYDROXYPHENYL)CYCLOALKENE COMPOUNDS AND USES THEREOF AS SELECTIVE AGONISTS OF THE ESTROGEN RECEPTOR BETA ISOFORM FOR ENHANCED MEMORY CONSOLIDATION | MARQUETTE UNIVERSITY (US) | 2018-10-04 | — | — | WO | disclosed |
| US-20170029711-A1 | HYDROCARBON SYNTHESIS METHODS, APPARATUS, AND SYSTEMS | SARTEC CORPORATION | 2017-02-02 | — | — | US | disclosed |
| US-9388345-B2 | Hydrocarbon synthesis methods, apparatus, and systems | SARTEC CORPORATION (US) | 2016-07-12 | — | — | US | disclosed |
| US-9382491-B2 | Hydrocarbon synthesis methods, apparatus, and systems | SARTEC CORPORATION (US) | 2016-07-05 | — | — | US | disclosed |
| US-20140115955-A1 | HYDROCARBON SYNTHESIS METHODS, APPARATUS, AND SYSTEMS | SARTEC CORPORATION | 2014-05-01 | — | — | US | disclosed |
| US-20140046104-A1 | HYDROCARBON SYNTHESIS METHODS, APPARATUS, AND SYSTEMS | SARTEC CORPORATION | 2014-02-13 | — | — | US | disclosed |
| WO-2014008355-A1 | HYDROCARBON SYNTHESIS METHODS, APPARATUS, AND SYSTEMS | MCNEFF CLAYTON V (US) | 2014-01-09 | — | — | WO | disclosed |
| EP-0482834-B1 | Process for producing alpha-hydroxyketones | TAKASAGO PERFUMERY CO LTD (JP) | 1996-01-17 | — | — | EP | disclosed |
| US-5210315-A | Oxidizing olefins using a ruthenium catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 1993-05-11 | — | — | US | disclosed |
| EP-0482834-A1 | Process for producing alpha-hydroxyketones | Takasago International Corporation (JP) | 1992-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327421-A1 | Substituted (4-Hydroxyphenyl)Cycloalkane and (4-Hydroxyphenyl)Cycloalkene Compounds and Uses Thereof as Selective Agonists of the Estrogen Receptor Beta Isoform for Enhanced Memory Consolidation | ESR2, GPER1, ESR1 | ABCB1 3079/4885DPP7 3780/4885TSHR 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.